Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback